On August 31, WUXI APPTEC fell 3.2% in regular trading, trading at HKD 191.7 per share with turnover of HKD 253 million, extending its recent corrective trend.

On the news front, the decline comes amid sustained selling pressure following the company's disposal of 53.524 million shares in WuXi XDC via block trade on August 26, raising approximately HKD 3.92 billion and generating an estimated pre-tax gain of around RMB 3.143 billion. This marks the fifth reduction in its WuXi XDC stake since November of the prior year, with cumulative proceeds reaching approximately HKD 10.87 billion. Additionally, JPMorgan's H-share holding ratio dropped from 12.09% to 10.90%, reinforcing institutional trimming signals that weighed on market sentiment. The company stated that proceeds from the asset disposal will be directed toward its core businesses.

Meanwhile, the broader Life Sciences Tools and Services sector saw widespread weakness, with WUXI BIO down 3.89%, GENSCRIPT BIO down 3.54%, WUXI XDC down 3.0%, INSILICO down 5.27%, and XTALPI down 4.01%, compounding downside pressure on WUXI APPTEC.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)